Anthera Pharmaceuticals (ANTH) Promotes Dr. Debra Odink as CTO
Tweet
Share
E-mailGet Alerts ANTH Hot Sheet
Join SI Premium – FREE
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) announced Dr. Debra Odink has been promoted to the role of Chief Technology Officer and Senior Vice President.
Dr. Odink joined Anthera in 2005 and has been serving as the Senior Vice President of Pharmaceutical Research and Development since that date. She has over eighteen years of global pharmaceutical chemistry and product development experience. Prior to joining Anthera, she served as the Vice President of Product and Process Development at Peninsula Pharmaceuticals.
Dr. Odink joined Anthera in 2005 and has been serving as the Senior Vice President of Pharmaceutical Research and Development since that date. She has over eighteen years of global pharmaceutical chemistry and product development experience. Prior to joining Anthera, she served as the Vice President of Product and Process Development at Peninsula Pharmaceuticals.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Seven Letter adds two staffers to its public affairs practice
- Entrée Resources names Chris Adams as new CEO effective July 17
- ViCentra names new CFO and adds board member ahead of U.S. expansion
Create E-mail Alert Related Categories
Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
